Doximity's Earnings Drop Signals a Pharma Ad Slowdown
Doximity shares dropped about 23% after a Q4 FY26 report that beat revenue — a move that says more about U.S. digital pharma ad budgets than about the company. This dated benchmark record breaks down the guidance gap, management's sub-5% ad-market assumption, and what the signal means for healthcare media buyers.
- Platform
- Doximity
- Campaign type
- Q0 FY26 earnings release
- Spend range
- FY0 revenue guidance $664M-$676M
- Timeframe
- 0-05-13 to 2026-05-14
- Stock price change
- -23%
- Verdict
- loss
- Industry vertical
- Pharma
- Last reviewed
- 0-08-25
| Date | Public move | What the move said at the time |
|---|---|---|
| Feb. 6, 2026 | Doximity fell about 17% to $27.75 after its Q3 FY26 guidance cut [1]. | A first public warning that the market was already re-pricing forward expectations, not just the quarter that had been reported [1]. |
| May 13–14, 2026 | Doximity dropped about 23% to a reported record low of $18.01 after Q4 FY26 revenue beat expectations but FY27 guidance landed well below consensus [2][3][4]. | The main advertising signal in this record: management’s forward view implied slower U.S. digital pharma ad budgets, even though the just-finished year still showed growth [2][3][4]. |
| Aug. 6–7, 2026 | The stock reversed sharply, with follow-up coverage describing a roughly 33% surge after Q1 FY27 results [9][10][11][12]. | A later price move that complicates the read, but does not cancel the May signal; it mainly shows how much of the tape was still short-interest driven [11][12]. |
This is an external sourced Benchmarks record, not first-party Signal & Convert campaign data. It is best read as a dated public signal on pharma ad budgets, not as a clean verdict on Doximity as a business. The May 13–14 print matters because the quarter itself was not the problem; the forward guide was.
What the May print actually changed
Doximity’s Q4 FY26 revenue came in at $145.4 million versus $143.91 million consensus, and the full year finished at $644.9 million, up 13%. Free cash flow reached $317.5 million, up 19%, and Q4 adjusted EBITDA was $65.8 million, a 45.3% margin [2].
The stock sold off because the next year looked softer: FY27 revenue guidance of $664 million to $676 million and adjusted EBITDA guidance of $323 million to $335 million both sat below the market’s expectations, which were near $697 million and $349.5 million [2][3]. Management’s FY27 planning assumption also put digital pharma ad-market growth likely at or below 5%; FY27 was framed as an AI investment year with no AI revenue contribution, and coverage tied the profit miss to AI compute costs [2][3][8].
The Q1 FY27 guide made the same point in smaller form: revenue was guided to $151 million to $152 million versus $153.25 million consensus [2][3].
- Established by the print: the current-year business was still growing, but management was bracing for slower ad-market growth and margin pressure [2][3].
- Not established by the print: a market-wide collapse across every healthcare channel or a structural break in Doximity’s operating model.
- Still to be pressure-tested: account-level pacing, client approvals, and later public updates.
Why buyers can use Doximity as a budget proxy
Doximity sits close to pharma marketing spend because its business is tied to healthcare and pharma advertisers [7]. That is why the market reaction mattered more than a normal earnings beat. By May 14, 2026, the stock was already about 47% down year to date and roughly 74% below its late-September 2025 high of $76.51 [5][6]. IBD also reported that the stock had sold off on every recent report, averaging a 6.6% drop on earnings day despite beats [6].
Analyst reactions reinforced that read. Coverage tied the move to Jefferies cutting the stock to Hold and its target to $19 from $51, Baird moving to Neutral at $18 from $40, and Goldman staying Neutral while trimming its target to $28 from $34 [4][5]. The Schall Law Firm investigation after the drop was another sign that the event had become a market story, not just a quarterly one [5].
The same public-report-to-budget method shows up in other benchmark reads, like Humana’s healthcare-budget signal pair and its MA cuts and paid ad strategy, where a public update is useful only if it changes the next planning conversation.
The August rebound complicated the tape, not the May signal
On Aug. 6–7, 2026, Doximity reported Q1 FY27 revenue of $156.6 million, up 7%, and raised FY27 revenue guidance only $6 million to $671 million to $681 million [9]. StockStory’s read of the call said the raise did not reflect a significant contribution from the expanding AI commercial pipeline [10]. CNBC and Schaeffers both framed the move against short-interest mechanics, with Schaeffers citing 20.73 million shares short, about 16% of float, and CNBC describing a similarly heavy short setup [11][12].
That follow-up matters because it shows how quickly a crowded short can reverse a stock, even after a rough guide. It does not change what the May 2026 print established for media buyers: the public signal pointed to slower growth in U.S. digital pharma ad budgets, and that read still needs to be checked against account-level pacing, client approvals, and later company updates.
References
- Doximity stock 17% weak guidance sparks an institutional sell-off — Trefis — Feb. 7, 2026 — link
- Doximity Announces Fourth Quarter and Fiscal Year 2026 Financial Results — Doximity Investor Relations — May 13, 2026 — link
- Doximity forecasts fiscal 2027 revenue of $664M-$676M amid AI investment year and softer pharma — Seeking Alpha — link
- Why Doximity Stock Plunged Today — Motley Fool via Yahoo Finance — link
- Why Is Doximity (DOCS) Stock Down -23% Today? — Tickeron — link
- Doximity Stock Crashes To Record Low As AI Trips LinkedIn For Doctors — Investor's Business Daily — link
- Company profile: Doximity — Umbrex — link
- Doximity sinks on gloomy full-year revenue outlook, says AI compute costs are weighing on margins — Sherwood News — link
- Doximity Announces Fiscal 2027 First Quarter Financial Results — Doximity Investor Relations — Aug. 6, 2026 — link
- Doximity (DOCS) Q1 CY2026 Deep Dive: AI Investments Accelerate Amid Macro and Policy Headwinds — StockStory — link
- Doximity shares double. Here's what's driving it. — CNBC — Aug. 7, 2026 — link
- LinkedIn for Doctors Stock Nearly Doubles After Earnings — Schaeffers Research — Aug. 7, 2026 — link
Built on this evidence
No Bidding tactic or Creative record currently cites this case file. Compare it against other results in Benchmarks.
Related benchmark reading
Report a corroborating or contradicting result
Seeing something different in your own account? Feed the data-integrity loop instead of leaving an open comment.